Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, has completed the acquisition of TWi Pharmaceutical, a technology-based company specializing in development and commercialization of niche generic drugs.
Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will significantly boost Bora’s service offerings in key areas, such as formulation development, sterile ophthalmic, and niche manufacturing technologies.
“The acquisition of TWi Pharmaceuticals marks a huge milestone in Bora’s history as we become the largest pharmaceutical group by volume in Taiwan,” said Bobby Sheng, CEO, Bora Pharmaceuticals. “TWi has a long history of strong formulation development, as well as an impeccable quality track record. As a result of acquiring TWi, Bora will be able to further expand on our capabilities as a full service CDMO. I’m looking forward to continuing our growth in this industry.”
